Hospital
Magnolia Regional Health System INC
Magnolia Regional Health System INC was paid $1.29M by Medicaid between Oct 2020 and Dec 2024, across 104 billing codes. Its largest line is 97110, Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion — 13% of everything it billed.
33Billing provider infoMAGNOLIA REGIONAL HEALTH SYSTEM INC
MAGNOLIA, AR 71753
MAGNOLIA, AR 71753
33aNPI1700407541assigned 05/04/2020
33bProvider typeCritical Access Hospital
28Total paid$1.29M
24GClaims68,601
24DCodes billed104
24AFirst – last monthOct 2020 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Arkansas
Rank by total paid#12 of 34
Median peer was paid$773K
This provider vs. median1.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 3,864 | $57K | |
| 2021 | 18,248 | $291K | |
| 2022 | 18,819 | $332K | |
| 2023 | 16,827 | $345K | |
| 2024incomplete | 10,843 | $262K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 13% | 5,768 | 1,154 | $165K |
| 87631 | 12% | 1,555 | 1,478 | $155K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 6.2% | 2,228 | 1,994 | $80K |
| 70450 | Computed tomography, head or brain; without contrast material | 5.9% | 866 | 786 | $76K |
| 80053 | Comprehensive metabolic panel | 5.6% | 5,523 | 4,648 | $72K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.5% | 514 | 451 | $58K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 4.0% | 7,637 | 6,275 | $51K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 3.8% | 822 | 720 | $49K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 3.6% | 1,115 | 994 | $47K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 3.5% | 2,645 | 2,151 | $45K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 3.5% | 985 | 927 | $45K |
| 97161 | 2.9% | 636 | 555 | $37K |
92 more codes
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.8% | 1,628 | $23K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.7% | 2,503 | $22K |
| 80050 | General health panel | 1.6% | 572 | $21K |
| 99283 | Emergency room visit (moderate) | 1.6% | 618 | $20K |
| 71046 | Radiologic examination, chest; 2 views | 1.5% | 1,216 | $20K |
| 71045 | Radiologic examination, chest; single view | 1.3% | 2,184 | $17K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.3% | 1,868 | $17K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.2% | 393 | $15K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 1.1% | 58 | $14K |
| 80061 | Lipid panel | <1% | 1,156 | $11K |
| 99284 | Emergency room visit (serious) | <1% | 485 | $11K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 329 | $10K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 43 | $10K |
| 84484 | <1% | 1,509 | $9K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,331 | $9K |
| 81025 | <1% | 1,031 | $8K | |
| 0001A | <1% | 211 | $8K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 409 | $8K |
| 0002A | <1% | 181 | $8K | |
| 82553 | <1% | 1,090 | $8K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 259 | $7K |
| 73560 | <1% | 210 | $7K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 858 | $7K |
| 83735 | <1% | 1,434 | $7K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 93 | $7K |
| 81001 | <1% | 2,332 | $6K | |
| 83690 | <1% | 934 | $6K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 161 | $6K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,065 | $6K |
| 82550 | <1% | 1,070 | $6K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 592 | $6K |
| 99285 | Emergency room visit (most serious) | <1% | 179 | $4K |
| 83880 | <1% | 256 | $4K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 81 | $4K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 81 | $4K |
| 82150 | <1% | 542 | $3K | |
| 83605 | <1% | 348 | $3K | |
| 85730 | <1% | 780 | $3K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 221 | $2K |
| 20610 | <1% | 104 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 158 | $2K |
| 85610 | <1% | 970 | $2K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 91 | $2K |
| 86756 | <1% | 134 | $2K | |
| 87186 | <1% | 573 | $2K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 24 | $2K |
| 81003 | <1% | 824 | $2K | |
| 83655 | <1% | 111 | $2K | |
| 73630 | <1% | 77 | $2K | |
| 82962 | <1% | 305 | $2K | |
| 74018 | <1% | 105 | $2K | |
| 80320 | <1% | 108 | $2K | |
| 87088 | <1% | 297 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 511 | $1K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 349 | $1K |
| 73130 | <1% | 43 | $886.69 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 13 | $860.00 |
| 73610 | <1% | 45 | $852.51 | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 12 | $785.27 |
| 87040 | <1% | 60 | $782.34 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 137 | $710.65 |
| 73562 | <1% | 28 | $694.37 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 97 | $515.16 |
| 0012A | <1% | 67 | $421.53 | |
| 86901 | <1% | 14 | $395.09 | |
| 0011A | <1% | 68 | $392.80 | |
| 84439 | <1% | 30 | $326.14 | |
| 73030 | <1% | 14 | $320.95 | |
| 80143 | <1% | 14 | $319.10 | |
| 80179 | <1% | 14 | $319.10 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 88 | $276.00 |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 974 | $252.25 |
| 72100 | <1% | 12 | $241.10 | |
| 82803 | <1% | 16 | $229.05 | |
| 84145 | <1% | 18 | $226.65 | |
| 82565 | <1% | 12 | $218.39 | |
| 85018 | <1% | 48 | $147.60 | |
| 82728 | <1% | 12 | $136.22 | |
| 82607 | <1% | 17 | $129.12 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 41 | $48.31 |
| 85651 | <1% | 13 | $47.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 34 | $29.76 |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 64 | $8.73 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 31 | $8.01 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 64 | $8.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 28 | $3.66 |
| G0008 | Administration of influenza virus vaccine | 0% | 15 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 42 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 13 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 18 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 19 | $0.00 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 20 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGILES, WILLIAM (CHIEF EXECUTIVE OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Magnolia Regional Health System INC | Magnolia, AR | $110K |
| Magnolia Regional Health System INC | Magnolia, AR | $47K |
| Magnolia Regional Health System INC | Magnolia, AR | $30K |
| Magnolia Regional Health System INC | Magnolia, AR | $20K |
| Magnolia Regional Health System INC | Magnolia, AR | $7K |
| Magnolia Regional Health System INC | Magnolia, AR | $2K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.